Obesity and Pulmonary Embolism: Can We Dismantle the “Obesity Paradox”

Publikationsverlauf

Eingereicht: 05. Oktober 2023

Angenommen: 05. Oktober 2023

Accepted Manuscript online:
06. Oktober 2023

Artikel online veröffentlicht:
15. November 2023

• References

• 1 Stoops H, Dar M. Equity and obesity treatment - expanding medicaid-covered interventions. N Engl J Med 2023; 388 (25) 2309-2311
• 2 Smith RA. The hidden career cost of being overweight. Wall Street Journal. 2023 July 24, 2023. Accessed October 16, 2023 at: https://www.wsj.com/articles/the-hidden-career-cost-of-being-overweight-68f4b8e7
• 3 Gaugler JO, Righini M, Robert-Ebadi H. et al. Obesity as a Predictor for pulmonary embolism and performance of the age-adjusted D-dimer strategy in obese patients with suspected pulmonary embolism. Thromb Haemost 2023; (e-pub ahead of print)
• 4 Gurunathan U, Barras M, McDougall C, Nandurkar H, Eley V. Obesity and the risk of venous thromboembolism after major lower limb orthopaedic surgery: a literature review. Thromb Haemost 2022; 122 (12) 1969-1979
• 5 Frischmuth T, Hindberg K, Gabrielsen ME. et al. Joint effect of multiple prothrombotic genotypes and obesity on the risk of incident venous thromboembolism. Thromb Haemost 2022; 122 (02) 267-276
• 6 Frischmuth T, Tøndel BG, Brækkan SK, Hansen JB, Morelli VM. The risk of incident venous thromboembolism attributed to overweight and obesity: the Tromsø Study. Thromb Haemost 2023; (e-pub ahead of print)
• 7 El-Menyar A, Asim M, Al-Thani H. Obesity paradox in patients with deep venous thrombosis. Clin Appl Thromb Hemost 2018; 24 (06) 986-992
• 8 Kalayci A, Gibson CM, Hernandez AF. et al. Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: observations from the APEX trial. Thromb Res 2022; 211: 63-69
• 9 Weitz JI, Farjat AE, Ageno W. et al; GARFIELD-VTE Investigators. Influence of body mass index on clinical outcomes in venous thromboembolism: insights from GARFIELD-VTE. J Thromb Haemost 2021; 19 (12) 3031-3043
• 10 Goldhaber SZ, Grodstein F, Stampfer MJ. et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997; 277 (08) 642-645
• 11 Righini M, Van Es J, Den Exter PL. et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA 2014; 311 (11) 1117-1124
• 12 Khan I, Chong M, Le A. et al. Surrogate adiposity markers and mortality. JAMA Netw Open 2023; 6 (09) e2334836
• 13 Kosiborod MN, Abildstrøm SZ, Borlaug BA. et al; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023; 389 (12) 1069-1084
• 14 Lingvay I, Brown-Frandsen K, Colhoun HM. et al; SELECT Study Group. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring) 2023; 31 (01) 111-122
• 15 Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial [press release]. Novo Nordisk. August 8, 2023